Research programme: thrombosis therapies - Selecore
Alternative Names: Anti-platelet therapeutics - SelecoreLatest Information Update: 18 May 2011
At a glance
- Originator Selecore
- Class Proteins
- Mechanism of Action Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 07 Sep 2005 Preclinical trials in Thrombosis in Germany (PO)